The second article in series of publications considering history of implementation of the government program of additional medication support from point of view of conditions of development of pharmaceutical market in Russia. The study is carried out on the basis both of interviews of participants of pharmaceutical market and state administrators and publications in specialized editions in 2020-2022. The first experience of close interaction of pharmaceutical business with government in implementation of social policy is analyzed. The focus is made on failures in practical implementation of the program of additional medication support, in which course alliance of government and pharmaceutical business cracked.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.32687/0869-866X-2023-31-4-658-664 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Characteristics of Virologically Confirmed Respiratory Syncytial Virus in English Primary Care: Protocol for an Observational Study of Acute Respiratory Infection.
JMIR Res Protoc
January 2025
Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Background: There are gaps in our understanding of the clinical characteristics and disease burden of the respiratory syncytial virus (RSV) among community-dwelling adults. This is in part due to a lack of routine testing at the point of care. More data would enhance our assessment of the need for an RSV vaccination program for adults in the United Kingdom.
View Article and Find Full Text PDFImproving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East.
Adv Ther
January 2025
School of Population Health, University of New South Wales, Sydney, Australia.
Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East.
View Article and Find Full Text PDFAutologous platelet concentrates as adjuncts to non-surgical periodontal therapy: a systematic review and meta-analysis.
Clin Oral Investig
January 2025
Periodontology Unit, Centre for Host Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, UK.
Objective: To evaluate the possible additional clinical benefit from autologous platelet concentrate (APC) treatment adjunct to non-surgical periodontal therapy (NSPT).
Methods: Electronic (MEDLINE/Embase/Cochrane/MedNar/CORE) and hand searches were conducted. Following studies selection, evidence tables were formed, and meta-analyses were performed for the following outcomes: probing pocket depth (PPD) reduction, clinical attachment level (CAL) gain, and bleeding on probing (BoP) reduction.
The multifaceted role of XCL1 in health and disease.
Protein Sci
February 2025
Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia.
The chemokine XC motif chemokine ligand 1 (XCL1) is an unusually specialized member of a conserved family of around 50 small, secreted proteins that are best known for their ability to stimulate the directional migration of cells. All chemokines adopt a very similar folded structure that binds a specific G protein-coupled receptor (GPCR), and most chemokines bind extracellular matrix glycosaminoglycans, often in a dimeric or oligomeric form. Owing in part to the lack of a disulfide bond that is conserved in all other chemokines, XCL1 interconverts between two distinct structures with distinct functions.
View Article and Find Full Text PDFMolecular Symphony of Mitophagy: Ubiquitin-Specific Protease-30 as a Maestro for Precision Management of Neurodegenerative Diseases.
CNS Neurosci Ther
January 2025
Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, USA.
Introduction: Mitochondrial dysfunction stands as a pivotal feature in neurodegenerative disorders, spurring the quest for targeted therapeutic interventions. This review examines Ubiquitin-Specific Protease 30 (USP30) as a master regulator of mitophagy with therapeutic promise in Alzheimer's disease (AD) and Parkinson's disease (PD). USP30's orchestration of mitophagy pathways, encompassing PINK1-dependent and PINK1-independent mechanisms, forms the crux of this exploration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!